Lord, H K <br/><br/>
Cetuximab is effective, but more toxic than reported in the Bonner trial.  [electronic resource] 

 -  Clinical oncology (Royal College of Radiologists (Great Britain))  Feb 2008 
 - 96 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>0936-6555 
<br/><br/><label>Standard No.: </label>10.1016/j.clon.2007.09.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Squamous Cell--drug therapy<br/>Cetuximab<br/>Female<br/>Humans<br/>Laryngeal Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Oropharyngeal Neoplasms--drug therapy